223 related articles for article (PubMed ID: 22310924)
1. Solifenacin for overactive bladder: a systematic review and meta-analysis.
Luo D; Liu L; Han P; Wei Q; Shen H
Int Urogynecol J; 2012 Aug; 23(8):983-91. PubMed ID: 22310924
[TBL] [Abstract][Full Text] [Related]
2. Which anticholinergic drug for overactive bladder symptoms in adults.
Madhuvrata P; Cody JD; Ellis G; Herbison GP; Hay-Smith EJ
Cochrane Database Syst Rev; 2012 Jan; 1():CD005429. PubMed ID: 22258963
[TBL] [Abstract][Full Text] [Related]
3. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Swift SE; Siami P; Forero-Schwanhaeuser S
Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of solifenacin in patients previously treated with tolterodine extended release 4 mg: results of a 12-week, multicenter, open-label, flexible-dose study.
Chancellor MB; Zinner N; Whitmore K; Kobashi K; Snyder JA; Siami P; Karram M; Laramée C; Capo' JP; Seifeldin R; Forero-Schwanhaeuser S; Nandy I
Clin Ther; 2008 Oct; 30(10):1766-81. PubMed ID: 19014833
[TBL] [Abstract][Full Text] [Related]
5. Comparisons of urodynamic effects, therapeutic efficacy and safety of solifenacin versus tolterodine for female overactive bladder syndrome.
Hsiao SM; Chang TC; Wu WY; Chen CH; Yu HJ; Lin HH
J Obstet Gynaecol Res; 2011 Aug; 37(8):1084-91. PubMed ID: 21501328
[TBL] [Abstract][Full Text] [Related]
6. Solifenacin and tolterodine are equally effective in the treatment of overactive bladder symptoms.
Ho CH; Chang TC; Lin HH; Liu SP; Huang KH; Yu HJ
J Formos Med Assoc; 2010 Oct; 109(10):702-8. PubMed ID: 20970066
[TBL] [Abstract][Full Text] [Related]
7. [Safety of solifenacin and tolterodine in the treatment of overactive bladder: a meta-analysis].
Xu C; Jiang XZ; Zhang NZ; Zhao HF; Xu ZS
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(48):3398-402. PubMed ID: 23327698
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes in the STAR study: a subanalysis of solifenacin 5 mg and tolterodine ER 4 mg.
Chapple CR; Fianu-Jonsson A; Indig M; Khullar V; Rosa J; Scarpa RM; Mistry A; Wright DM; Bolodeoku J;
Eur Urol; 2007 Oct; 52(4):1195-203. PubMed ID: 17574730
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder.
Chapple CR; Rechberger T; Al-Shukri S; Meffan P; Everaert K; Huang M; Ridder A;
BJU Int; 2004 Feb; 93(3):303-10. PubMed ID: 14764127
[TBL] [Abstract][Full Text] [Related]
10. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Goepel M
Urologe A; 2006 Jul; 45(7):847-51. PubMed ID: 16816976
[No Abstract] [Full Text] [Related]
11. [Comment on the STAR study: Comparison of the efficacy and tolerance of solifenacin and tolterodine retard in the treatment of overactive bladder].
Chapple C
Urologe A; 2007 Apr; 46(4):422, 424-6; author reply 426, 428. PubMed ID: 17384923
[No Abstract] [Full Text] [Related]
12. Re: Chapple CR, Martinez-Garcia R, Selvaggi L, Toozs-Hobson P, Warnack W, Drogendijk T, Wright DM, Bolodeoku J. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. Eur Urol 2005;48:464-70.
Jonas U; Rackley RR
Eur Urol; 2006 Jan; 49(1):187-8; author reply 188-90. PubMed ID: 16310930
[No Abstract] [Full Text] [Related]
13. Therapeutic benefit in patients switching tolterodine to other novel antimuscarinic agents.
Sánchez-Ballester F; Miranda P; Lizarraga I; Rejas J; Arumi D
Actas Urol Esp; 2014 Apr; 38(3):156-63. PubMed ID: 24119382
[TBL] [Abstract][Full Text] [Related]
14. A cost-utility analysis of once daily solifenacin compared to tolterodine in the treatment of overactive bladder syndrome.
Speakman M; Khullar V; Mundy A; Odeyemi I; Bolodeoku J
Curr Med Res Opin; 2008 Aug; 24(8):2173-9. PubMed ID: 18565239
[TBL] [Abstract][Full Text] [Related]
15. Pharmacologic management of overactive bladder.
Lam S; Hilas O
Clin Interv Aging; 2007; 2(3):337-45. PubMed ID: 18044184
[TBL] [Abstract][Full Text] [Related]
16. Benefits and harms of pharmacologic treatment for urinary incontinence in women: a systematic review.
Shamliyan T; Wyman JF; Ramakrishnan R; Sainfort F; Kane RL
Ann Intern Med; 2012 Jun; 156(12):861-74, W301-10. PubMed ID: 22711079
[TBL] [Abstract][Full Text] [Related]
17. [Comparisons of therapeutic efficacy and safety of solifenacin versus tolterodine in patients with overactive bladder: a meta-analysis of outcomes].
Liu B; Li P; Li J; Wang Y; Wu Y
Zhonghua Yi Xue Za Zhi; 2014 Aug; 94(30):2350-4. PubMed ID: 25399976
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of solifenacin in patients aged ≥ 65 years with overactive bladder: post-hoc analysis of 2 open-label studies.
Capo' JP; Lucente V; Forero-Schwanhaeuser S; He W
Postgrad Med; 2011 Jan; 123(1):94-104. PubMed ID: 21293089
[TBL] [Abstract][Full Text] [Related]
19. Number of daytime micturitions and volume voided per micturition in the evaluation of efficacy of drugs for overactive bladder: findings from randomized clinical trials.
Colli E; Parazzini F; Olivieri L; Cipriani S; Bertozzi R; Meschia M; Montorsi F
Eur Urol; 2007 Aug; 52(2):525-30. PubMed ID: 17449169
[TBL] [Abstract][Full Text] [Related]
20. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.
Gacci M; Novara G; De Nunzio C; Tubaro A; Schiavina R; Brunocilla E; Sebastianelli A; Salvi M; Oelke M; Gravas S; Carini M; Serni S
BMC Urol; 2014 Oct; 14():84. PubMed ID: 25348235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]